ZGNX Stock
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ZGNX — AI-powered stock analysis, price $26.68, MoonshotScore 71/100.
Price live · AI analysis from Jul 5, 2026Analyst Coverage for ZGNX: ZGNX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ZGNX against Healthcare peers across nine fundamental dimensions and assigns a relatively strong fundamental profile based on the underlying data.
ZGNX: 3/7 perspectives are bullish. Dominant signal: Ken Griffin bullish.
How is this calculated? →ZGNX Company Overview
Who Are ZGNX's Competitors?
ZGNX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| TSRO Tesaro, Inc. | $74.96 | +0.00% | 71 | |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $98.95M | 71 |
| KROS Keros Therapeutics, Inc. | $11.18 | -0.71% | $357.74M | 71 |
| CVAC CureVac N.V. | $4.66 | +0.00% | $1.05B | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are the Key Risks for ZGNX?
- Negative return on equity (-82.9%) — the business is not currently generating profit on shareholder capital.
How ZGNX Is Valued
Relative to its peer group, ZGNX's quantitative score of 71/100 is roughly in line with the peer average of 76/100.
Company Profile
ZGNX operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Emeryville, US. The company is led by CEO Stephen Farr. ZGNX has traded publicly since 2010.
ROE -83%Key Financial Metrics
Return on equity for ZGNX stands at -82.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -48.5%, showing how much profit it generates from its asset base. A current ratio of 3.63 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.9%, the inverse of the P/E and a quick read on earnings relative to price.
ZGNX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
ZGNX Latest News
-
Stocks That Hit 52-Week Lows On Thursday
· Feb 27, 2020
-
Stocks That Hit 52-Week Lows On Wednesday
· Feb 26, 2020
-
Stocks That Hit 52-Week Highs On Friday
· Jan 17, 2020
ZGNX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ZGNX.
Price Targets
Wall Street price target analysis for ZGNX.
ZGNX MoonshotScore
What does this score mean?
The MoonshotScore rates ZGNX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
What Investors Ask About ZGNX (ZGNX)
What are the key factors to evaluate for ZGNX?
Evaluate ZGNX on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does ZGNX data refresh on this page?
ZGNX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ZGNX's recent stock price performance?
ZGNX moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZGNX overvalued or undervalued right now?
Valuing ZGNX requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ZGNX?
Before investing in ZGNX, research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ZGNX to a portfolio?
The case for ZGNX depends on individual goals and risk tolerance. Weigh rewards against risks and diversify. Not financial advice.
Can I buy fractional shares of ZGNX?
Yes, most major brokerages offer fractional shares of ZGNX with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ZGNX's earnings and financial reports?
ZGNX reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for ZGNX earnings announcements is recommended.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.